Navigation Links
Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
Date:7/21/2009

ROCKVILLE, Md., July 21 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of John J. Trizzino as Senior Vice President, International and Government Alliances, a new senior officer position. Mr. Trizzino will report directly to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer, and assume responsibility for developing and managing the company's international alliances with pharmaceutical companies and all governmental agencies, including the US.

Previously, Mr. Trizzino was Vice President of the vaccine franchise at MedImmune, Inc., Senior Vice President of business development at ID Biomedical, and served as Vice President within the Henry Schein, Inc. medical division in business development and General Manager of their GIV division.

Dr. Singhvi stated: "John Trizzino is a talented executive with more than 28 years of broad corporate experience with the last 12 years focused on the vaccine and biotech market. He has managed a number of important flu vaccine products, including FluMist and Fluviral (Flulaval by GSK), created profitable global marketing partnerships, and worked closely with public and private partners including the U.S. Centers for Disease Control and Prevention's national immunization program and the Department of Health and Human Services. In addition, Mr. Trizzino's responsibilities at MedImmune and work with the RSV (Respiratory Syncytial Virus) market should be most valuable to Novavax as we continue development of our own RSV vaccine. I am excited to have him join our Company and look forward to his contributions to our rapidly expanding vaccine business."

Mr. Gary C. Evans, Lead Director of Novavax, commented, "Novavax continues to expand its footprint both here in the US and in the international markets. This is an important new position for our Company and is reflective of the continued evolution of Novavax in the vaccine space. John brings a unique blend of skills in vaccine product positioning strategy, government relations, and commercial markets to augment our existing management team to capitalize on the new opportunities available to the Company."

Mr. Trizzino is a graduate of Long Island University and received his master's degree in business administration from New York University's Stern School of Business.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Repayment of $5 Million of Convertible Debt
2. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
3. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
4. Novavax Appoints Stanley Erck to Board of Directors
5. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
7. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
8. Novavax Reports First Quarter 2009 Financial Results
9. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Early Retirement of $17 Million of Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... (PRWEB) , ... February 04, ... ... conference presented by Bloomsburg University’s Digital Forensics Club, takes place February 5-6 ... two-day event features 20+ speakers and activities such as workshops and competitions ...
(Date:2/4/2016)... --> --> Q BioMed ... provide the following update on recent corporate developments. ... months we have significantly increased our cash position through several ... result, we have positioned ourselves to execute on the initial ... that development to continue on schedule. --> ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
Breaking Biology Technology:
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):